|
1
|
D'Costa ZC, Higgins C, Ong CW, Irwin GW,
Boyle D, McArt DG, McCloskey K, Buckley NE, Crawford NT,
Thiagarajan L, et al: TBX2 represses CST6 resulting in uncontrolled
legumain activity to sustain breast cancer proliferation: A novel
cancer-selective target pathway with therapeutic opportunities.
Oncotarget. 5:1609–1620. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang B, Lindley LE, Fernandez-Vega V,
Rieger ME, Sims AH and Briegel KJ: The T box transcription factor
TBX2 promotes epithelial-mesenchymal transition and invasion of
normal and malignant breast epithelial cells. PLoS One.
7:e413552012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Han Y, Tu WW, Wen YG, Yan DW, Qiu GQ, Peng
ZH and Zhou CZ: Increased expression of TBX2 is a novel independent
prognostic biomarker of a worse outcome in colorectal cancer
patients after curative surgery and a potential therapeutic target.
Med Oncol. 30:6882013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vance KW, Carreira S, Brosch G and Goding
CR: Tbx2 is overexpressed and plays an important role in
maintaining proliferation and suppression of senescence in
melanomas. Cancer Res. 65:2260–2268. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu WK, Jiang XY and Zhang ZX: Expression
of PSCA, PIWIL1, and TBX2 in endometrial adenocarcinoma. Onkologie.
33:241–245. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Baldwin RL, Tran H and Karlan BY: Loss of
c-myc repression coincides with ovarian cancer resistance to
transforming growth factor beta growth arrest independent of
transforming growth factor beta/Smad signaling. Cancer Res.
63:1413–1419. 2003.PubMed/NCBI
|
|
7
|
Li J, Ballim D, Rodriguez M, Cui R, Goding
CR, Teng H and Prince S: The anti-proliferative function of the
TGF-β1 signaling pathway involves the repression of the oncogenic
TBX2 by its homologue TBX3. J Biol Chem. 289:35633–35643. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jerome-Majewska LA, Jenkins GP, Ernstoff
E, Zindy F, Sherr CJ and Papaioannou VE: Tbx3, the ulnar-mammary
syndrome gene, and Tbx2 interact in mammary gland development
through a p19Arf/p53-independent pathway. Dev Dyn. 234:922–933.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Redmond KL, Crawford NT, Farmer H, D'Costa
ZC, O'Brien GJ, Buckley NE, Kennedy RD, Johnston PG, Harkin DP and
Mullan PB: T-box 2 represses NDRG1 through an EGR1-dependent
mechanism to drive the proliferation of breast cancer cells.
Oncogene. 29:3252–3262. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rowley M, Grothey E and Couch FJ: The role
of Tbx2 and Tbx3 in mammary development and tumorigenesis. J
Mammary Gland Biol Neoplasia. 9:109–118. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vance KW, Shaw HM, Rodriguez M, Ott S and
Goding CR: The retinoblastoma protein modulates Tbx2 functional
specificity. Mol Biol Cell. 21:2770–2779. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Balogová L, Maslaňáková M, Dzurová L,
Miškovský P and Stroffeková K: Bcl-2 proapoptotic proteins
distribution in U-87 MG glioma cells before and after hypericin
photodynamic action. Gen Physiol Biophys. 32:179–187. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hojabrpour P, Waissbluth I, Ghaffari M,
Cox ME and Duronio V: CaMKII-γ mediates phosphorylation of BAD at
Ser170 to regulate cytokine-dependent survival and proliferation.
Biochem J. 442:139–149. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chao DT and Korsmeyer SJ: BCL-2 family:
Regulators of cell death. Annu Rev Immunol. 16:395–419. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Adams JM and Cory S: The Bcl-2 apoptotic
switch in cancer development and therapy. Oncogene. 26:1324–1337.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Courtney KD, Corcoran RB and Engelman JA:
The PI3K pathway as drug target in human cancer. J Clin Oncol.
28:1075–1083. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chang F, Lee JT, Navolanic PM, Steelman
LS, Shelton JG, Blalock WL, Franklin RA and McCubrey JA:
Involvement of PI3K/Akt pathway in cell cycle progression,
apoptosis, and neoplastic transformation: A target for cancer
chemotherapy. Leukemia. 17:590–603. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bertram J, Peacock JW, Tan C, Mui AL,
Chung SW, Gleave ME, Dedhar S, Cox ME and Ong CJ: Inhibition of the
phosphatidylinositol 3′-kinase pathway promotes autocrine
Fas-induced death of phosphatase and tensin homologue-deficient
prostate cancer cells. Cancer Res. 66:4781–4788. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tan XL, Guo L and Wang GH: Polyporus
umbellatus inhibited tumor cell proliferation and promoted tumor
cell apoptosis by downregulating AKT in breast cancer. Biomed
Pharmacother. 83:526–535. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Radisky DC and LaBarge MA:
Epithelial-mesenchymal transition and the stem cell phenotype. Cell
Stem Cell. 2:511–512. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bonavida B and Baritaki S: Inhibition of
Epithelial-to-Mesen chymal Transition (EMT) in cancer by nitric
oxide: Pivotal roles of nitrosylation of NF-κB, YY1 and Snail. For
Immunopathol Dis Therap. 3:125–133. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang J, Mani SA, Donaher JL, Ramaswamy S,
Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A and
Weinberg RA: Twist, a master regulator of morphogenesis, plays an
essential role in tumor metastasis. Cell. 117:927–939. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kang Y and Massagué J:
Epithelial-mesenchymal transitions: Twist in development and
metastasis. Cell. 118:277–279. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ferrara N: VEGF as a therapeutic target in
cancer. Oncology 69 Suppl. 3:11–16. 2005. View Article : Google Scholar
|
|
26
|
Kowanetz M and Ferrara N: Vascular
endothelial growth factor signaling pathways: Therapeutic
perspective. Clin Cancer Res. 12:5018–5022. 2006. View Article : Google Scholar : PubMed/NCBI
|
